| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Gain Therapeutics, Inc. | CEO, President, Director | Stock Option (right to buy) | 271,325 | $1,172,000 | $5.86 | 06 Jan 2025 | Direct |
| Gain Therapeutics, Inc. | CEO, President, Director | Common Stock | 14,400 | $14,544 | $1.01 | 09 Aug 2024 | Direct |
| Gain Therapeutics, Inc. | CEO, President, Director | Employee Stock Option (right to buy) | 200,000 | 20 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | 20 Mar 2025 | 1 | $0 | 4 | CEO, President, Director | 21 Mar 2025, 20:00 |
| GANX | Gain Therapeutics, Inc. | 06 Jan 2025 | 1 | $0 | 4 | CEO, President, Director | 07 Jan 2025, 21:00 |
| GANX | Gain Therapeutics, Inc. | 09 Aug 2024 | 1 | $14,544 | 4 | CFO and Interim CEO | 12 Aug 2024, 17:23 |
| GANX | Gain Therapeutics, Inc. | 08 Apr 2024 | 1 | $0 | 4 | Chief Financial Officer | 08 Apr 2024, 19:44 |
| GANX | Gain Therapeutics, Inc. | 05 Apr 2024 | 0 | $0 | 3 | Chief Financial Officer | 08 Apr 2024, 19:42 |